Key result
Dihydropyridine CCBs lead antihypertensive use in kidney transplant recipients at ~56% prevalence, alongside beta-blockers.
Why the study?
Hypertension is common among kidney transplant recipients, but data regarding antihypertensive medication use patterns in this population are limited.
What are the patterns and correlates of antihypertensive medication use in adult kidney transplant recipients?
Observational
Yes
What are the patterns and correlates of antihypertensive medication use in adult kidney transplant recipients?
Answers are grounded in this paper and cite their sources.
Contrary to general population guidelines, kidney transplant recipients are prescribed relatively more beta-blockers and fewer ACEi/ARBs, with significant variation across transplant centers.
Hypertension guidelines recommend calcium channel blockers (CCBs), thiazide diuretics, and angiotensin-converting-enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) as first-line agents to treat hypertension. Hypertension is common among kidney transplant (KTx) recipients, but data are limited regarding patterns of antihypertensive medication (AHM) use in this population. We examined a novel database that links national registry data for adult KTx recipients (age > 18 years) with AHM fill records from a pharmaceutical claims warehouse (2007-2016) to describe use and correlates of AHM use during months 7-12 post-transplant. For patients filling AHMs, individual agents used included: dihydropyridine (DHP) CCBs, 55.6%; beta-blockers (BBs), 52.8%; diuretics, 30.0%; ACEi/ARBs, 21.1%; non-DHP CCBs, 3.0%; and others, 20.1%. Both BB and ACEi/ARB use were significantly lower in the time period following the 2014 Eighth Joint National Committee (JNC-8) guidelines (2014-2016), compared with an earlier period (2007-2013). The median odds ratios generated from case-factor adjusted models supported variation in use of ACEi/ARBs (1.51) and BBs (1.55) across transplant centers. Contrary to hypertension guidelines for the general population, KTx recipients are prescribed relatively more BBs and fewer ACEi/ARBs. The clinical impact of this AHM prescribing pattern warrants further study.
No takes yet. Share an insight, caveat, or question.
Koraishy et al. (2020) conducted an observational in Kidney transplantation. Antihypertensive medications was evaluated on Antihypertensive medication use. Among adult kidney transplant recipients, dihydropyridine CCBs and beta-blockers were the most commonly used antihypertensive medications.
Synapse has enriched 10 related papers. Consider them for comparative context: